A national survey of 1,000 U.S. adults found that 52% support obtaining peptides legally through a licensed pharmacy with a doctor's prescription, while only 3% oppose it and 45% remain undecided. Among those with an opinion, the approval ratio is 19 to 1 in favor. This survey was conducted ahead of the FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, which will consider allowing seven peptides to regain lawful compounding pathways. The results highlight strong public interest in regulated peptide access as opposed to unregulated grey-market sources.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
Firm Capital Property Trust reported a 21% increase in Net Operating Income (NOI) to $11.7 million for Q3 2026 compared to the previous year, driven by high occupancy rates across its diversified portfolio. Net income rose to $7.0 million, and Adjust...
Ovintiv reported strong third quarter 2026 results with net earnings of $549 million and cash from operations of $1.1 billion. The company produced 631 thousand barrels of oil equivalent per day and invested $563 million in capital expenditures, whil...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
Weis Markets reported a 3.0% increase in total revenue to $1.28 billion for Q3 2026, driven by higher fuel sales and new store openings despite challenges like pharmacy pricing pressures and lower produce demand. Net income rose 31.4% to $22.21 milli...
